Blood Eosinophil Count

Eosinophils are a type of white blood cell central to allergic and type-2 inflammation. The count comes free with any routine full blood count — you almost certainly already have one in your record — and in respiratory medicine it has become one of the most practically useful numbers there is.

This is a rare example of a genuinely actionable biomarker, and it is quietly under-used. In COPD, the blood eosinophil count is what guides whether an inhaled corticosteroid will help — high counts predict benefit, low counts predict little benefit while the pneumonia risk remains. In asthma it identifies the eosinophilic phenotype and, at the severe end, determines eligibility for biologic therapies that have transformed outcomes. A number sitting unread on an existing blood test is deciding treatment for millions of people who have never heard of it.

1. 1

   FoundationHealthy AgingThe best place to understand what genuinely preserves healthspan.
2. 2

   ConditionAsthmaA disease of inflammation — treated by most people as a disease of wheezing
3. 3

   Signal RecordInhaled CorticosteroidsThe preventer inhaler — the one that saves lives, and the one people skip
4. 4

   Body SystemImmuneDefense, inflammation, and resilience to illness.
5. 5

   BiomarkerHigh-Sensitivity CRPA marker of low-grade inflammation

1. Measure it
2. Understand your result
3. See what raises and lowers it
4. Apply evidence-based interventions
5. Recheck on your review cadence

An orientation to how this topic is typically approached — not medical advice.

A persistently elevated count in someone with airway disease points to type-2 (eosinophilic) inflammation, which is the inflammation that inhaled and systemic corticosteroids — and the newer biologics — are designed to suppress. A very high count warrants a search for other causes, including parasitic infection and drug reactions.

• Included in a routine full blood count — no extra test required
• Best measured when not taking oral corticosteroids, which suppress the count
• Repeat rather than relying on a single value

Blood eosinophil count predicts response to inhaled corticosteroids in COPD, with higher counts associated with greater reduction in exacerbations; this relationship is reflected in major guideline recommendations for eosinophil-guided therapy. In asthma, it identifies the eosinophilic phenotype and is used to determine eligibility for biologic therapies targeting type-2 inflammation. Counts are suppressed by corticosteroid treatment and vary between measurements, so thresholds are treated as decision aids rather than diagnostic boundaries.

• GOLD strategy — eosinophil-guided inhaled corticosteroid therapy in COPD
• Post-hoc and prospective analyses of inhaled corticosteroid trials stratified by blood eosinophil count
• GINA strategy — phenotyping in severe asthma

Sources are named authoritative guidelines and scientific bodies. Biomarker pages present established clinical context; calibrated evidence verdicts on specific interventions live in the linked Signal Records.